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Abstract Over 70 transthyretin (TTR) mutations have been
associated with hereditary amyloidoses, which are all autosomal
dominant disorders with adult age of onset. TTR is the main
constituent of amyloid that deposits preferentially in peripheral
nerve giving rise to familial amyloid polyneuropathy (FAP), or in
the heart leading to familial amyloid cardiomyopathy. Since the
beginning of this decade the central question of these types of
amyloidoses has been why TTR is an amyloidogenic protein with
clinically heterogeneous pathogenic consequences. As a result of
amino acid substitutions, conformational changes occur in the
molecule, leading to weaker subunit interactions of the
tetrameric structure as revealed by X-ray studies of some
amyloidogenic mutants. Modified soluble tetramers exposing
cryptic epitopes seem to circulate in FAP patients as evidenced
by antibody probes recognizing specifically TTR amyloid fibrils,
but what triggers dissociation into monomeric and oligomeric
intermediates of amyloid fibrils is largely unknown. Avoiding
tetramer dissociation and disrupting amyloid fibrils are possible
avenues of therapeutic intervention based on current molecular
knowledge of TTR amyloidogenesis and fibril structure. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Transthyretin (TTR) amyloidosis is a systemic form of
amyloidosis that is in the vast majority an hereditary disease.
Over 70 di¡erent TTR mutations have been described associ-
ated with amyloid deposition; typical manifestations are pe-
ripheral neuropathy, cardiomyopathy, carpal tunnel syndrome
and vitreous opacities. Peripheral neuropathy is the main
symptom in familial amyloid polyneuropathy (FAP), while
cardiomyopathy constitutes the main or the sole clinical
symptom in familial amyloid cardiomyopathy (FAC) [1].
Non-mutated TTR can also deposit as amyloid in the heart
of old people, a condition termed senile systemic amyloidosis.
TTR is a plasma protein composed of four identical subunits
with an extended L-sheet conformation, as revealed by X-ray
crystal structure [2]. Several amyloidogenic variants have their
crystal structure determined and while some of them do not
show signi¢cant di¡erences from the wild-type (WT) protein,
others point to a transmission of structural events, associated
with the mutation, which destabilize the quaternary protein
structure. It is current opinion that the modi¢ed TTR repre-
sents an amyloidogenic intermediate, which integrates the ¢-
bril structure [3] ; analyses of FAP ¢brils have proved that
TTR in the ¢brils maintains a L-conformation and suggested
that the TTR monomer is the building block in ¢brils [4].
Further studies on native and synthetic TTR ¢brils using
high-resolution structural techniques will further elucidate ¢-
bril structure and the aggregation pathway. This review sum-
marizes current trends in research in TTR aggregation to-
wards prevention and treatment.
2. Amyloidogenic conformations
The 3D structure of TTR has an extensive L-sheet struc-
ture; each monomer contains two L-sheets, composed of
strands DAGH and CBEF, which interact face-to-face
through hydrogen bonds between strands HHP and FFP to
form a dimer. In the tetramer (represented in Fig. 1), hydro-
gen bonds between main chain atoms belonging to loop AB of
one monomer and strand HP from the other monomer as well
as hydrophobic contacts are important. The e¡ects introduced
by amyloidogenic mutations have been intensively studied in
an attempt to identify conformational changes rendering the
molecule vulnerable to aggregation. Among naturally occur-
ring TTR mutations Val30Met is the most common and was
the ¢rst to be crystallized and studied by X-ray di¡raction. No
major changes (as compared to the known 3D structure of the
WT protein) were detected except for a movement of cysteine
residue 10 opening a channel that runs through the molecule,
where the thyroid hormone thyroxine (T4) binds [5]. One of
the consequences of this change is an altered binding a⁄nity
of T4 for TTR. Another amyloidogenic mutation studied by
X-ray crystallography was isoleucine 122, which lies in the
region where two TTR dimers assemble to form a tetramer.
Again in this case no drastic structural changes were observed,
except for weaker bonding at dimer^dimer contacts [6]. This
¢nding was in accordance with earlier speculations in the be-
ginning of the decade that mutations in TTR may change
subunit self-assembly properties, weakening interactions be-
tween subunits [7]. TTR Leu55Pro has received much atten-
tion because it is associated with a highly aggressive form of
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FAP. X-ray studies on this mutant revealed drastic changes
brought about by the mutation leading to aggregation of TTR
having monomers as building blocks [8]. This is consistent
with data from synchrotron analyses of ‘ex vivo’ ¢brils [4]
and indicated important changes in secondary structure by
the disruption of strand D, which becomes part of a long
loop that connects strands C and E. Disruption of the D
strand a¡ects the hydrogen bonding with the A strand, expos-
ing new surfaces involved in aggregation; in particular, the
contacts of the K-helix and the AB loop are di¡erent, suggest-
ing these regions are important in amyloidogenesis. In fact,
deletion or multiple substitutions in the D strand lead to
highly amyloidogenic mutants. When monoclonal antibodies
were raised against these aggressive mutants, one particular
antibody did not recognize native TTR but only TTR ¢brils
[9]. Furthermore, this antibody was able to discriminate be-
tween sera from FAP patients and sera from control individ-
uals [10], suggesting that TTR from carriers of amyloidogenic
mutants circulates in a modi¢ed soluble form. In an attempt
to identify early soluble intermediates of the ¢brillogenesis
cascade, a mutant TTR, TTR Thy78Phe, was generated by
site-directed mutagenesis having the contacts between the K-
helix and the AB loop destabilized (as evidenced in the X-ray
structure of the Leu55Pro mutant). This mutant is recognized
in its soluble form by the above-mentioned monoclonal anti-
body, speci¢c for the amyloid fold, and represents a putative
early modi¢cation in the cascade leading to TTR aggregation
[11]. In the Tyr78Phe mutant, the hydrophobic interactions
are changed at dimer^dimer interfaces and less stable tet-
ramers with higher propensity for amyloid formation are gen-
erated. Thus, mutations in TTR that loose the AB loops of
the tetramer and other dimer^dimer interactions increase the
susceptibility of amyloid formation.
3. Self-assembly
Self-assembly properties of di¡erent TTR mutants have
been widely investigated by di¡erent approaches.
Studies on the in£uence of TTR mutations on tetrameric
stability showed dissociation into non-native monomeric spe-
cies at physiological pH, followed by self-association of this
intermediate into amyloid ¢brils [3,12]. This was possibly due
to subtle conformational modi¢cations that occur in the TTR
molecule before dissociation into monomers with altered ter-
tiary structure. These authors had previously established a
relation between the amyloidogenic potential of TTR variants
and the decreased stability of the tetramer, with subsequent
dissociation to monomeric species, with the Leu55Pro variant
being the less stable mutant [13]. Colon and Kelly [14] were
the ¢rst to present evidence for the existence of amyloidogenic
intermediates after partial acid denaturation. This amyloido-
genic intermediate was postulated to contain most of the na-
tive structure except for the rearrangement involving strands
C and D. In this model, FAP mutations would not a¡ect the
structure of the folded state (tetramers) but would favor the
denaturation pathway and/or degradation pathway(s) for
TTR turnover.
Self-assembly properties were particularly investigated with
studies on a non-amyloidogenic TTR, TTR Thr119Met. This
mutant is frequent in Portugal, and compound heterozygotic
individuals for Met30/Met119 have been found to exhibit a
more benign form of the disease. Comparative studies of am-
yloidogenic TTR Val30Met and the non-amyloidogenic TTR
Thr119Met by semi-denaturing isoelectric focusing revealed
that TTR Val30Met has a higher tendency for dissociation
of the tetramer into monomers than the WT TTR. In con-
trast, Thr119Met showed higher resistance to dissociation into
monomers than the WT protein, in addition, TTR from com-
pound heterozygotes Met30/Met119 behaved like WT TTR
[15]. Thus, one possible way by which Thr119Met can exert
anti-amyloidogenic e¡ects is by counteracting the weaker sub-
unit interactions of Met30 tetramers. Recent X-ray studies on
the Thr119Met mutant revealed that new hydrogen bonds
within each monomer and monomer^monomer intersubunit
contacts increase protein stability possibly leading to the pro-
tective e¡ect of the TTR Met30/Met119 variant when com-
pared to the single variant TTR Val30Met [16].
4. Drug design: tetrameric stabilizers and ¢bril disrupters
The protective stabilizing e¡ect of the Thr119Met mutation
on the Val30Met weaker subunit interaction is, in fact, the
basis for the rational design of drugs in TTR amyloidosis. The
Fig. 1. 3D structure of TTR. The L-strands of one monomer are in-
dicated by letters A to H.
Fig. 2. TTR tetrameric stabilizers and ¢bril disrupters as potential
drugs in the treatment of TTR amyloidosis.
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aim is at binding TTR in the central hydrophobic channel
that runs through the molecule, where the hydrophobic hor-
mone T4 binds, to prevent dissociation into monomers (see
Fig. 2). X-ray crystallographic analyses of di¡erent TTR^sta-
bilizer complexes have elucidated the binding modes in the
hormone binding cavity and contacts between adjacent TTR
subunits [17]. So far, these drugs have been shown to act ‘in
vitro’ but ‘in vivo’ studies to make them relevant for clinical
use are much awaited. Sul¢te has been shown both ‘in vitro’
and ‘in vivo’ to prevent TTR tetramers from dissociating but
the structural basis for this e¡ect has not been elucidated [18].
Another class of drugs with potential application in TTR
amyloidosis are ¢bril disrupters (see Fig. 2). Recently, 4P-de-
oxy-4Piododoxorubicin (IDOX) has been proved useful as a
tool for disrupting TTR amyloid ¢brils [19]. The amyloid
disrupters might also prove useful for amyloidoses associated
with other protein precursors, such as the L protein in Alz-
heimer and the prion scrapie protein. Due to its cardiotoxic-
ity, IDOX analogues able to disrupt amyloid ¢brils are
needed. The molecular interactions between IDOX and
Leu55Pro TTR ‘amyloid-like’ oligomer have been theoreti-
cally modeled [20], allowing the design of analogues with ¢bril
disrupting properties.
5. Final remarks
Growing knowledge on the molecular events leading to
TTR aggregation makes possible the development of thera-
peutic agents; however, better therapeutics will be possible
when more is known on other aspects of this fascinating
group of diseases, namely on genetic and environmental mod-
ulators of phenotypic expression and on the mechanisms of
cell death, aspects not reviewed here.
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